284 related articles for article (PubMed ID: 23158694)
1. Small molecules in the treatment of systemic lupus erythematosus.
Markopoulou A; Kyttaris VC
Clin Immunol; 2013 Sep; 148(3):359-68. PubMed ID: 23158694
[TBL] [Abstract][Full Text] [Related]
2. Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus.
Kyttaris VC; Tsokos GC
Curr Opin Rheumatol; 2011 Sep; 23(5):449-53. PubMed ID: 21720246
[TBL] [Abstract][Full Text] [Related]
3. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors.
Bonilla-Hernán MG; Miranda-Carús ME; Martin-Mola E
Rheumatology (Oxford); 2011 Sep; 50(9):1542-50. PubMed ID: 21622522
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
5. Novel small molecule therapeutics in rheumatoid arthritis.
Kelly V; Genovese M
Rheumatology (Oxford); 2013 Jul; 52(7):1155-62. PubMed ID: 23297340
[TBL] [Abstract][Full Text] [Related]
6. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
Richter P; Cardoneanu A; Burlui AM; Macovei LA; Bratoiu I; Buliga-Finis ON; Rezus E
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233087
[TBL] [Abstract][Full Text] [Related]
7. The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways.
Kenkre VP; Kahl BS
Curr Hematol Malig Rep; 2012 Sep; 7(3):216-20. PubMed ID: 22688757
[TBL] [Abstract][Full Text] [Related]
8. Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus.
Iwata S; Yamaoka K; Niiro H; Jabbarzadeh-Tabrizi S; Wang SP; Kondo M; Yoshikawa M; Akashi K; Tanaka Y
Lupus; 2015 Jun; 24(7):695-704. PubMed ID: 25432781
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.
Patterson H; Nibbs R; McInnes I; Siebert S
Clin Exp Immunol; 2014 Apr; 176(1):1-10. PubMed ID: 24313320
[TBL] [Abstract][Full Text] [Related]
10. Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling.
Grammatikos AP; Ghosh D; Devlin A; Kyttaris VC; Tsokos GC
PLoS One; 2013; 8(8):e74550. PubMed ID: 24013589
[TBL] [Abstract][Full Text] [Related]
11. Promising new treatments for rheumatoid arthritis - the kinase inhibitors.
Yazici Y; Regens AL
Bull NYU Hosp Jt Dis; 2011; 69(3):233-7. PubMed ID: 22035435
[TBL] [Abstract][Full Text] [Related]
12. Targeting spleen tyrosine kinase-Bruton's tyrosine kinase axis for immunologically mediated glomerulonephritis.
Chen JS; Chang LC; Huang SJ; Cheng CW
Biomed Res Int; 2014; 2014():814869. PubMed ID: 24795896
[TBL] [Abstract][Full Text] [Related]
13. From mechanism to therapies in systemic lupus erythematosus.
Paley MA; Strand V; Kim AH
Curr Opin Rheumatol; 2017 Mar; 29(2):178-186. PubMed ID: 28118202
[TBL] [Abstract][Full Text] [Related]
14. [Involvement of Syk in pathology of systemic autoimmune disease].
Iwata S; Yamaoka K; Niiro H; Nakano K; Wang SP; Saito K; Akashi K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):56-61. PubMed ID: 22374444
[TBL] [Abstract][Full Text] [Related]
15. Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy.
Lo MS; Tsokos GC
Curr Opin Rheumatol; 2018 Mar; 30(2):222-228. PubMed ID: 29206660
[TBL] [Abstract][Full Text] [Related]
16. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
Norman P
Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
[TBL] [Abstract][Full Text] [Related]
17. Molecular abnormalities of the B cell in systemic lupus erythematosus are candidates for functional inhibition treatments.
Liossis SN; Melissaropoulos K
Expert Opin Pharmacother; 2014 Apr; 15(6):833-40. PubMed ID: 24588739
[TBL] [Abstract][Full Text] [Related]
18. The Jakinibs in systemic lupus erythematosus: progress and prospects.
Mok CC
Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
[TBL] [Abstract][Full Text] [Related]
19. Bruton's tyrosine kinase in systemic lupus erythematosus.
Liao HT; Tung HY; Tsai CY; Chiang BL; Yu CL
Joint Bone Spine; 2020 Dec; 87(6):670-672. PubMed ID: 32473417
[No Abstract] [Full Text] [Related]
20. Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus.
Nakayamada S; Tanaka Y
Expert Rev Clin Immunol; 2022 Mar; 18(3):245-252. PubMed ID: 35138987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
